Vtesse, Inc.

Financings Total biopharma financing during the fourth quarter of 2017 amounted to $14.5 billion, a strong finish to a year that benefitted from renewed investor confidence in the industry and an open

Mallinckrodt PLC has agreed to acquire Sucampo Pharmaceuticals Inc. for $1.2bn, including the assumption of the latter's debt. The deal most notably brings one significant marketed asset, and tw

Impact Biomedicines has closed a structured financing for up to $90m – just two weeks after launching with $22.5m in venture capital – that will support commercialization of its JAK2 inhibitor fedra

Biopharma start-up fundraising more than doubled to $3.87bn in the second quarter versus the prior quarter, helped by initial public offerings, including the Actelion Pharmaceuticals Ltd. spinout